Effectiveness and safety of enzyme replacement therapy in the treatment of Fabry disease: a Chinese monocentric real-world study

Table 3 Renal function data of patients at baseline and the last test during ERT

Subjects	Sort	Patients																Mean ± SD	P
Subjects	Sort	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	Mean ± SD	P
eGFR(mL/min/1.73 m²)	Baseline	85.3	80.8	6.1	90.1	64.3	105.6	100.1	87.4	112.6	6.0	102.8	167.0	145.5	51.4	22.3	186.5	88.4 ± 51.8	0.836
eGFR(mL/min/1.73 m²)	Last test	81.0	95.6	6.1	91.6	64.8	106.2	108.9	104.3	114.8	12.1	108.5	147.6	107.6	50.8	18.9	168.3	86.7 ± 46.1
mALB(mg/L)	Baseline	395	139						1			664	9	24	7	967	23	248 ± 353	0.208
mALB(mg/L)	Last test	166	209						1			1257	35	6	8	3072	30	531 ± 1033
24 h PRO(g/24 h)	Baseline	1.38	0.51			1.49	0.10			0.44		1.16	0.09	0.24	0.10	3.72	0.36	0.87 ± 1.1	0.593
24 h PRO(g/24 h)	Last test	1.29	1.30			0.69				0.44								0.93 ± 0.4
ACR(mg/g)	Baseline	913	367						4			788	9	8	15	3393	25	614 ± 1102	0.859
ACR(mg/g)	Last test	623	106						4			1990	11	4	9	4999	52	867 ± 1681
UA(μmol/L)	Baseline	250	461	298	217	456	320	265	233	343	433	430	269	151	267	438	139	311 ± 106	0.918
UA(μmol/L)	Last test	281	411	279	233	502	219	255	208	339	197	406	291	169	351	476	203	301 ± 103
β2MG(mg/L)	Baseline	2.7	1.6	43.6	1.8	3.5	1.5	1.9	2.3	2.5	24.2	3.8	1.4	1.2	2.3	6.6	1.4	6.4 ± 11.4	0.732
β2MG(mg/L)	Last test	2.6	2.4	48.7	1.5	3.4	1.8	1.3	1.5	1.6	47.4	3.1	1.4	1.1	1.9	6.7	1.5	8.0 ± 15.7

ERT enzyme replacement therapy, eGFR estimated glomerular filtration rate, mALB microalbumin (reference value 0.0–30.0 mg/L), 24 h PRO 24 h urine protein quantification (reference value 0.00–0.15 g/24 h), ACR urinary albumin/creatinine ratio (reference value 0.0–30.0 mg/g), UA uric acid (reference value 208–428 μmol/L), β2 mg β2 microglobulin (reference value 0.8–2.8 mg/L)

ISSN: 1750-1172